Abstract
Cullin 3 (CUL3) is part of the ubiquitin proteasomal system and controls several cellular processes critical for normal organ function including the cell cycle, and Keap1/Nrf2 signaling. Kidney tubule-specific Cul3 disruption causes tubulointerstitial fibrosis, but little is known about the mechanisms. Therefore, we tested the hypothesis that dysregulation of the cell cycle and Keap1/Nrf2 pathway play a role in initiating the kidney injury upon Cul3 disruption. Cul3 deletion increased expression of cyclin E and p21, associated with uncontrolled proliferation, DNA damage, and apoptosis, all of which preceded proximal tubule injury. The cdk2-cyclin E inhibitor roscovitine did not prevent the effects of Cul3 deletion, but instead exacerbated the kidney injury. Injury occurred despite accumulation and activation of CUL3 substrate Keap1/Nrf2, proposed to be protective in kidney injury. Cul3 disruption led to progressive interstitial inflammation, functionally relevant renal fibrosis and death. Finally, we observed reduced CUL3 expression in several AKI and CKD mouse models and in fibrotic human kidney tissue. These data establish CUL3 knockout mice as a novel genetic CKD model in which dysregulation of the cell cycle may play a primary role in initiating tubule injury, and that CUL3 dysregulation could contribute to acute and fibrotic kidney disease.
Introduction
Sustained acute kidney injury (AKI) transitions into chronic kidney disease (CKD) with the development of tubulointerstitial fibrosis as the final endpoint1. However, the mechanisms involved are poorly understood, and their identification will be the first step towards an urgently needed therapy for the vast and growing CKD patient population.
Covalent linkage of ubiquitin to proteins (ubiquitination) plays a pivotal role in determining cellular function2, but its role in kidney fibrosis is largely unexplored3. Cullin 3 (CUL3), a member of the Cullin-RING ligase (CRL) family of ubiquitin ligases, is highly conserved and present in all human organs. Its disruption results in embryonic lethality4,5. CUL3 is absent from the glomerulus, but is expressed along all tubule segments, with highest mRNA and protein levels in proximal tubule4,6. In the CRL, CUL3 acts as a scaffold protein for the RING ubiquitin ligase, and for an array of substrate-binding adaptors that confer substrate-specificity.
CUL3 is involved in multiple intracellular pathways7 including those activated by Wnt/β-catenin8, Hedgehog/Gli9, NF-kB10, Notch11, Keap1/Nrf212 and cell cycle proteins5,13, all reported to be critical in kidney injury and fibrosis. In humans, Cul3 mutations are associated with renal cell carcinoma14 and cause the disease Familial Hyperkalemic Hypertension (FHHt, also known pseudohypoaldosteronism II)15. We previously generated doxycycline-inducible renal epithelia-specific Cul3 knockout (KS-Cul3−/−) mice to investigate mechanisms underlying FHHt6. These mice display a complex phenotype, with increased activation of the thiazide-sensitive Na+-Cl− cotransporter (NCC), and polyuria due to a loss of aquaporin-2 (AQP2). Chronically, they displayed histological signs of tubulointerstitial fibrosis and increased expression of the CUL3 substrate cyclin E, but the originating tubule segment, the pathways dysregulated, and the time-course of the development of renal injury were not determined. Therefore, the aims of this study were to i) identify the site of acute tubule injury upon Cul3 deletion and to characterize the time-course of its transition into CKD, thus, establishing KS-Cul3−/− mice as a novel genetic CKD model; ii) test the hypothesis that dysregulation of the cell cycle and Keap1/Nrf2 pathway precedes tubule injury, and that the cyclin E inhibitor roscovitine ameliorates kidney injury; iii) test the hypothesis that CUL3 plays a broader role in kidney disease by examining CUL3 expression in mouse models of AKI and CKD, and in fibrotic human samples.
Results
Increased proliferation and DNA damage precedes proximal tubule injury following Cul3 disruption
To generate inducible renal-epithelia-specific Cul3 knockout mice, Cul3flox/flox mice were interbred with Pax8-rtTA/LC1 transgenic mice as previously described6,16. In this system the reverse tetracycline transactivator (rtTA) is constitutively expressed under the control of the Pax8 promoter, which is active within the kidney along the entire renal epithelia. Doxycycline administered in drinking water binds to the rtTA which then promotes transcription of Cre recombinase from the LC1 transgene, leading excision of exons 4–7 at the “floxed” Cul3 allele. Thus, disruption of Cul3 is doxycycline-inducible, almost exclusively along the renal epithelia, in adult mice. To determine early effects of Cul3 disruption and test the hypothesis that cell cycle dysregulation contributes to the initiation of injury, doxycycline was administered for 6, 9 or 12 days to disrupt Cul3. Maximal Cul3 disruption was observed after 6 days (Fig. 1a,b). Mild acute tubule injury was detected after 9 and 12 days of Cul3 deletion, based on semi-quantification of periodic acid-Schiff (PAS)-stained slides (Fig. 1c,d). Haemotoxylin & Eosin (H&E) stained kidney sections are shown in Supplementary Fig. S1a. Immunofluorescence (IF) revealed kidney injury molecule-1 (KIM-1)+ signal in KS-Cul3−/− mice at day 9 and 12, which coincided with lower Lotus tetragonolobus lectin (LTL)- signal in proximal tubules (PT), indicating acute tubule injury (Fig. 1e,f). From day 6 on, a progressive increase in Ki-67+ proliferating cells in KS-Cul3−/− mice was observed (Fig. 1e,g). At day 6, the majority of Ki-67+ cells were localized in (LTL)-positive proximal tubules (PT) and Ki-67 was detected in both uninjured and injured PT, and in interstitial cells (Fig. 1e,g). Signal for the DNA damage marker γ-H2AX followed the same pattern as Ki-67 (Fig. 1h,i). IF for cleaved caspase-3 revealed that Cul3 deletion induced apoptosis in PT cells at day 9 and 12 (see Supplementary Fig. S1b,c). De novo CD44 expression suggested that injury did not occur in glomeruli (no CD44+ parietal epithelial cells), but was restricted to PT (see Supplementary Fig. S1d).
A recent RNA-sequencing study reported that following ischemia/reperfusion injury (IRI), mRNA abundance of KIM-1 increased and peaked prior to induction of Ki-6717. This reported sequence appeared to be the opposite of changes in KIM-1 and Ki-67 protein in KS-CUL3−/− mice. Therefore, we examined wild-type mice that had undergone unilateral IRI to permit direct comparison with our data from KS-Cul3−/− mice at the protein level. 4 h after IRI, KIM-1 signal was still absent and only a low number of Ki-67+ cells was observed in both injured and contralateral non-injured kidney (Fig. 1j,l). 18 h after IRI, we observed an increase of Ki-67+ cells in KIM-1+ PT and adjacent interstitium in the injured kidney (Fig. 1j,l). Changes in γ-H2AX expression followed a similar pattern to that of Ki-67 following IRI (Fig. 1k,m). These observations were consistent with morphological signs of damage as seen by PAS and H&E staining (see Supplementary Fig. S2a,b). Thus, the injuries induced by Cul3 disruption and IRI differ, with increased proliferation and DNA damage occurring prior to KIM-1+ PT injury in KS-CUL3−/− mice, but occurring simultaneously following IRI. Uncontrolled proliferation, DNA damage and apoptosis may therefore drive the proximal tubule injury in KS-Cul3−/− mice.
Dysregulation of cell cycle proteins and Keap1-Nrf2 signaling precede injury following Cul3 disruption
CUL3 modulates abundances of the cell cycle protein cyclin E5, and of Keap1/Nrf218, key players in oxidative stress response. These systems have been implicated in AKI and CKD19,20, and importantly, both cyclin E5 and Keap121 are directly ubiquitinated and targeted for proteasomal degradation by CUL3. We hypothesized that both pathways are activated in KS-CUL3−/− mice, but cyclin E effects on uncontrolled proliferation and DNA damage override protective effects of Keap1/Nrf2. Western blotting revealed significantly higher abundances of cyclin E and its inhibitor p21, as well as of Keap1 and NQO1, a readout of Nrf2 activity, within 12 days of Cul3 disruption (Fig. 2a–e). Consistent with IF (Fig. 1e,f,h), KIM-1 was only detected at significant levels at later time-points (Fig. 2a,f). Thus, while the Keap1-Nrf2 pathway was activated prior to injury in KS-CUL3−/− mice, its potential protective effects were overridden by effects of Cul3 disruption on other pathways.
Following IRI, consistent with IF (Fig. 1j,k), KIM-1 signal was detectable 18 h after IRI, and signal abundance increased further at days 3 and 7 (Fig. 2g,h). In contrast to KS-CUL3−/− mice, changes in cyclin E, p21, Keap1, NQO1 occurred after KIM-1 induction (Fig. 2g–l). Furthermore, p21 and NQO1 abundances were significantly lower in the injured kidney than in the contralateral kidney (Fig. 2g,j,l).
Cul3 disruption causes sustained proximal tubule injury and inflammation
To determine the time-course of kidney injury, we analyzed mice 2, 4 and 8 weeks after initiating Cul3 deletion (Fig. 3a,b). PAS staining showed progressive acute tubule injury characterized mainly by brush border loss, epithelial flattening, tubule dilation and intratubular debris (Fig. 3c,d). H&E staining showed similar kidney morphology (see Supplementary Fig. S3a). At week 8, there was a significant loss of LTA+ brush border, suggesting continued PT injury (Fig. 3e). This was supported by increased abundances of KIM-1, Neutrophil gelatinase-associated lipocalin (NGAL), cleaved caspase-3, γ-H2AX and Ki-67 over the time course (Fig. 3f–i,l–o; see Supplementary Fig. S3b–e). Infiltrating cells were positive for the T-cell marker CD3 (Fig. 3j,p) or macrophage marker F4/80 (Fig. 3k,q; see Supplementary Fig. S3f), but other infiltrating cell types may also have been present.
Cul3 disruption causes progression into renal fibrosis and persistent cell cycle dysregulation
IF staining revealed accumulation of fibronectin and collagen 1 in Cul3 disrupted kidneys within 4 weeks (Fig. 4a–d). CUL3 protein was not completely ablated (Fig. 3a,b), and co-staining for CUL3 and alpha smooth muscle actin (α-SMA), another surrogate marker for fibrosis, revealed accumulation of α-SMA+ interstitial myofibroblasts in areas lacking CUL3 (Fig. 4e,f). These data indicate that disruption of Cul3 causes sustained tubule injury with transition into CKD, thus establishing KS-Cul3−/− mice as a genetically-inducible CKD model.
Cyclin E abundance increases upon IRI, peaks and then returns to pre-injury levels within 14 days17. In our model, Cul3 disruption is irreversible leading to a persistent injury. Western blotting revealed that abundance of cyclin E continued to increase from weeks 2 to 8, while p21 abundance was maximal and did not increase further after 2 weeks (Fig. 4g,i). Compared to controls, IF for markers more specific to different cell cycle phases revealed upon Cul3 disruption increased number of cells positive for PCNA (maximal at the S phase), Bromodeoxyuridine (BrdU) (S phase) and phospho-Histone 3 (pH3) (Fig. 4j–o), the latter of which has been reported as a marker for G2/M phase arrest22. These data suggest that Cul3 disruption leads to persistent cell cycle dysregulation, causing tubule cells to enter into the cell cycle, and at least partially to arrest in the profibrotic G2/M phase22.
Since cyclin E abundance was increased in KS-CUL3−/− mice, we determined whether roscovitine, an inhibitor of cyclin-dependent kinases (cdk) including Cdk2-cyclin E, could ameliorate the effects of Cul3 disruption by co-administration with doxycycline during induction of Cul3 deletion (Fig. 5a). Roscovitine had no effect on abundances of CUL3, cyclin E or p21 in control or KS-CUL3−/− mice compared with vehicle-treated mice (Fig. 5b–e). Cul3 disruption leads to polyuria due to loss of AQP26. Roscovitine-treated KS-Cul3−/− mice tended to have lower AQP2 levels than vehicle-treated KS-Cul3−/− mice (Fig. 5b,f), Roscovitine exacerbated the effects of Cul3 disruption on kidney injury (Fig. 5g–j), and apoptosis (Fig. 5l,m). Roscovitine did not significantly affect DNA damage (Fig. 5i,k) and proliferation in KS-CUL3−/− mice (Fig. 5n,o). Roscovitine exacerbated the effects of Cul3 disruption on polyuria (Fig. 5p).
Chronic Cul3 disruption results in death from renal failure
7–8 months after induction of Cul3 disruption, mice displayed increased mortality (Fig. 6a). We sacrificed the remainder of the cohort for analyses. Blood chemistry revealed hyperkalemia, anemia, and elevated blood urea nitrogen (Table 1), typical features of late CKD. Histology revealed severe global renal fibrosis and mild to moderate glomerulosclerosis (Fig. 6b,c), and Picrosirius red staining revealed high levels of collagen deposition (Fig. 6d,e). Glomerular filtration rate (GFR) measurements revealed a progressive decline in kidney function 16 weeks after induction of Cul3 disruption (Fig. 6f). Diuresis peaked 8 weeks after Cul3 disruption then decreased despite persistently lower AQP2 abundance (Fig. 6g–i). Thus, the declining diuresis is likely due to renal failure. Urinary albumin did not differ at baseline or at 4 or 26 weeks between controls and KS-CUL3−/− mice, but in KS-CUL3−/− mice it was significantly elevated from baseline at 26 weeks (Fig. 6j). This suggests that glomerular damage is not a primary feature of the phenotype, consistent with Cul3 disruption specifically along renal epithelia.
Table 1.
Blood Parameters | CTRL | KS-Cul3−/− | P value |
---|---|---|---|
Sodium (mmol/L) | 146 ± 0.2 | 153 ± 1.8 | 0.001 |
Potassium (mmol/L) | 4.2 ± 0.1 | 5.9 ± 0.5 | 0.003 |
Chloride (mmol/L) | 111 ± 0.9 | 109 ± 1.1 | 0.147 |
Ionized Calcium (mmol/L) | 1.3 ± 0 | 1.1 ± 0 | 0.006 |
Total Carbon Dioxide (mmol/L) | 23 ± 1.5 | 28 ± 0.6 | 0.027 |
Blood Urea Nitrogen (mg/dL) | 22 ± 1.5 | 129 ± 11.2 | 0.001 |
Creatinine (mg/dL) | 0.2 ± 0 | 0.8 ± 0.1 | 0.001 |
Hematocrit (% PCV) | 35 ± 1.7 | 22 ± 2.7 | 0.001 |
Hemaglobin (g/dL) | 11.9 ± 0.6 | 7.4 ± 0.9 | 0.001 |
Anion Gap (mmol/L) | 17 ± 1.1 | 21 ± 0.9 | 0.218 |
Body weight (g) | 30.1 ± 1.9 | 16.8 ± 1.2 | 0.001 |
KS-Cul3−/− mice display CKD phenotype. Hyperkalemia, renal failure, anemia and other abnormal blood values 8 months after Cul3 deletion. Data represent the mean ± SEM. P values were calculated by unpaired, two-tailed, t test obtained from 8 CTRL vs. 5 KS-Cul3−/− mice.
Decreased nuclear CUL3 localization is associated with renal injury in animal models and humans
Since lower CUL3 signal correlated with tubule injury and fibrosis, we next asked whether CUL3 expression might be affected in commonly used AKI/CKD mouse models, and in human kidney fibrosis. IF on consecutive sections 72 h after IRI revealed decreased signal for CUL3 in most KIM-1+ tubules in the injured kidney (Fig. 7a). However, Ki-67 expression did not completely correlate with lower CUL3 signal (Fig. 7a). Decreased CUL3 signal was also observed 14 days after IRI (Fig. 7b). Furthermore, following unilateral ureteral obstruction (UUO) or nephrotoxic nephritis (NTN), tubules with less CUL3 signal were surrounded by α-SMA+ areas (Fig. 7c,d). In human kidney, lower nuclear CUL3 signal was observed in areas with high-grade fibrosis than in areas with low-grade fibrosis (Fig. 7e).
Discussion
We found that induced tubule-specific CUL3 deletion in adult mice caused sustained proximal tubule injury, followed by interstitial inflammation, progressive fibrotic renal disease and death. This establishes KS-CUL3−/− mice as a novel animal model of CKD and implicates CUL3 as major upstream player in several pathways within the kidney. Cul3 disruption caused dysregulation of the cell cycle characterized by uncontrolled proliferation, DNA damage and apoptosis prior to tubule injury, and increased Nrf2 activity upon Cul3 deletion could not prevent the development of fibrosis. In contrast, ischemia-induced tubule injury preceded and triggered changes in cell cycle proteins and Keap1-Nrf2 signaling, suggesting the mechanisms involved in tubule injury differ between the two models.
Since CUL3-mediated degradation of cyclin E is required for cells to maintain a quiescent state5, loss of CUL3 in renal epithelia resulted in constant overexpression of cyclin E and hence proliferation. Deregulation of cyclin E turnover results in chromosomal instability, DNA damage and apoptosis23,24, which were all observed following Cul3 disruption. These findings are consistent with previous reports in which fibroblast or hepatocyte-specific deletion of Cul3 resulted in proliferation and polyploidy as well as chromosome breakage, micronuclei formation, and apoptosis24,25. DNA damage can itself induce transcription of p21, causing cell cycle arrest by inhibition of cyclin E and other targets26. We observed increased abundance of p21 upon Cul3 deletion. Most evidence to-date suggests that p21 is a substrate of Cul1skp2 and Cul4ACdt2-mediated degradation27,28, so it remains to be determined whether this was a direct result of Cul3 deletion or secondary to DNA damage and other cell-cycle effects. Interestingly, it has been shown that increased expression of p21 in proximal tubules results in increased TGF-β mRNA, and vice versa, mediating kidney fibrosis29. IRI induced a proliferative response, supporting the well-characterized role of the cell cycle in adaptive (and maladaptive) repair after kidney injury20. In contrast, persistent proliferation was induced prior to kidney injury in KS-CUL3−/− mice, which likely causes cell cycle dysregulation and DNA damage, and may drive the injury. However, roscovitine did not have beneficial effects by suppressing cell cycle entry in KS-CUL3−/− mice, but exacerbated kidney injury and apoptosis. Roscovitine is a broad-range purine analog inhibitor, which in addition to inhibiting cdk2/cycline E, targets other cell cycle components including cdk1, cdk5, cdk7, and cdk930. In cancer cell lines, which are highly proliferative, roscovitine not only arrests the cell cycle, but also induces apoptosis31. Therefore, since Cul3 disrupted tubules displayed uncontrolled proliferation, roscovitine may have caused further cell cycle dysregulation and apoptosis in these mice. This speculation is supported by the observation that roscovitine had no effect in control mice, consistent with previous reports in which administration of roscovitine was well-tolerated in healthy mice31,32.
CUL3 and its adaptor Keap1 mediate degradation of Nrf2, a master regulator of anti-oxidant responses18. Mouse models and clinical trials in humans suggest that activation of Nrf2 or inhibition of Keap1 ameliorate AKI severity and slow CKD progression33–35. However, the recent demonstration that Nrf2 activation can result in chronic inflammation and kidney fibrosis by NFκB10 and the NLRP3 inflammasome36 questions the consensus that Nrf2 exerts beneficial effects in renal fibrosis. We show that Keap1/Nrf2 activity is elevated in KS-CUL3−/− mice, suggesting a central role for CUL3 in regulating anti-oxidant responses in the kidney. Furthermore, other pathways (e.g. Hedgehog/Gli) related to kidney fibrosis are regulated by CUL3, and further studies including transcriptomic and proteomic analyses will be required to assess the full effects of Cul3 disruption, particularly in the early phase. A recent transcriptomics analysis reported that the chemokine CXCL12 induced CUL3 expression in a human fibroblast cell line, and this was associated with procollagen secretion37. Pharmacological blockade of CUL3 activation prevented CKCL12-induced procollagen secretion, suggesting a direct role for CUL337. However, in this study37, CUL3 was upregulated in fibroblasts while here we disrupted Cul3 in tubule epithelia, so it remains to be determined whether selective inhibition of CUL3 in e.g. (myo-)fibroblasts may ameliorate kidney fibrosis upon injury.
Similarly to CUL3 knockout mice, in other mouse models of acute or chronic injury, reduced CUL3 signal was associated with increased proximal tubule injury and fibrosis, and reduced CUL3 was also observed in highly fibrotic human tissue. Altered CUL3 activity may therefore contribute to the overall proliferative response and activation of several profibrotic pathways in injury. Recent work highlights the proximal tubule as the primary sensor and effector of the AKI-CKD transition38. Our data support the idea that an isolated tubule injury can cause peritubular inflammation, interstitial fibrosis, and renal functional decline. Various mouse models have identified several pathways that may be targeted to slow down progression of CKD, but good animal models of tubulointerstitial fibrosis are lacking39. Current genetic models are mainly restricted to disruption of glomerular proteins, and the few tubule-specific CKD models involve non-inducible conditional genetic modifications or modifications in non-proximal tubule segments39–42. Here, we present a mouse model which permits the induction of sustained proximal tubule injury within 1–2 weeks in adult mice. One limitation is that Cul3 deletion along the entire nephron leads to a complex phenotype including polyuria, so a future refinement will be to use an inducible proximal tubule-specific Cre driver43. Despite this limitation, our model recapitulates many features of CKD seen in humans and may provide insights into how tubular injury facilitates progressive kidney fibrosis. Shifting our attention from the late features of CKD to the early responses of the proximal tubule could lead to novel therapeutic targets, and identification of the CUL3 substrates involved may serve as a starting point.
Methods
Animals
Animal studies were performed in adherence to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the OHSU Institutional Animal Care and Use Committee (protocol IP00286) and by LANUV (Germany) (9.93.2.10.35.07.041, 8.87–50.10.35.08.254). All experiments and methods were performed in accordance with relevant guidelines and regulations. Inducible renal epithelia-specific Cul3 knockout mice were generated by interbreeding Pax8-rtTA/LC1 transgenic mice with Cul3flox/flox mice as reported6. Cul3 disruption was induced by administration of 2 mg/ml doxycycline in drinking water with 5% sucrose (vehicle) up to 2 weeks. Controls received vehicle for the same duration as the doxycycline exposure. Males and females were both used, were 8 to 14 weeks of age at time of doxycycline, vehicle or roscovitine treatment, and had ad libitum access to drinking water and standard chow.
Murine renal injury models
Wild type C57BL/6 mice were used between 8 to 14 weeks of age for injury studies. For IRI, the left kidney was exposed through flank incision and was subjected to ischemia by clamping the left renal pedicle for 28 minutes at 36.5 °C to 37.5 °C body temperature44. The clamp was removed and the kidney was reperfused. Mice were sacrificed 4 h, 18 h, 3 days, 7 days, and 14 days post-surgery. For UUO, left kidney was exposed through flank incision and the ureter was tied off at the level of the lower pole with two 4.0 silk ties45. Mice were sacrificed 14 days post-surgery. Nephrotoxic nephritis was induced by a single intraperitoneal injection of 5 mg/g nephrotoxic serum46. Mice were sacrificed 7 days post-injection.
Human samples
Use of human kidney samples was approved by the ethics committee of the University Hospital RWTH Aachen (EK 221/16) and informed consent was obtained from all participants. All experiments and methods were performed in accordance with relevant guidelines and regulations. Research was conducted in accordance with the Declaration of Helsinki. Unaffected renal tissue from patients with renal carcinoma was provided by the Eschweiler-Aachen Biobank. As described44, fibrosis severity was scored in PAS-stained sections and samples were stratified into low-grade fibrosis (fibrosis grade ≤20%) and high-grade fibrosis (fibrosis grade ≥40%) groups. Blinded to clinical data, 3 samples per group were selected, and sections stained for CUL3.
Antibodies and chemicals
A detailed list of antibodies and chemicals is provided in Supplementary Table S1.
Roscovitine
Roscovitine was dissolved in 5% DMSO, 50% PEG300, 45% H2O and injected i.p. at 50 mg/kg body weight once daily for 20 days. The dose was chosen based on previous reports47,48.
Western Blot
As described49, 40 μg protein of whole kidney lysates were separated on 4–12% Bis-tris acetate gels and transferred to polyvinylidene fluoride membrane. Membranes were blocked with 5% non-fat milk in TBS-Tween, followed by incubation with primary antibody and HRP-coupled secondary antibody. Using Western Lightning ECL, signal was detected with a Syngene Pxi4 imager, and densitometry was performed with ImageJ. Actin abundance can change in response to experimental manipulation, so we normalized by densitometric quantitation of total protein via Coomassie staining49,50. Coomassie gels are shown in Supplementary Fig. S4.
Histology, Immunofluorescence (IF) and Immunohistochemistry
Kidneys were perfusion-fixed with 4% paraformaldehyde, and 5 µm paraffin sections were stained with H&E, PAS, and Picrosirius Red by the OHSU Histopathology Core. Acute tubule damage was semi-quantified on PAS-stained slides by scoring extent of (a) brush border loss in proximal tubules, (b) epithelial cell flattening and (c) vacuolization51. Each phenomenon was separately scored as: 0, absent; 1, slightly present; 2 moderately present; and 3, severely present. The percentage representation of each score was estimated and multiplied by the score itself (i.e. leading to values in the range 0–300; e.g. 100% severely present brush border loss would reach the score 3 × 100 = 300) The tubule injury score of each animal was expressed by adding the scores for brush border loss, epithelial flattening and vacuolization (i.e. leading to values in the range 0–900). For IF, sections were incubated for 2 h at room temperature with primary antibodies in 1%BSA/PBS, followed by Cy2, Cy3 or Cy5-conjugated secondary antibodies (all 1:500, ThermoFisher Scientific) for 1 h at room temperature, and stained with DAPI in mounting medium. Immunohistochemistry was performed with Vectastain ABC Kit, according to the manufacturer’s instructions.
Blood analysis
Blood was collected via cardiac puncture and loaded into a Chem8+cartridge for electrolyte measurement by i-STAT analyzer (Abbot Point of Care Inc.).
Glomerular filtration rate (GFR) and urinalysis
GFR was measured by determining elimination of fluorescein isothiocyanate (FITC)-sinistrin transcutaneously as described52. A fluorescence detector (NIC-Kidney; Mannheim Pharma & Diagnostics GmbH, Germany) was placed on a depilated region of the mouse’s back and FITC-sinistrin (75 mg/kg body weight) was injected retro-orbitally. Data were acquired in conscious freely-moving mice for 60–120 min and GFR calculated using the half-life (t1/2). 36 h after GFR measurements, 24 h urine was collected in metabolic cages (Hatteras Inc.) to measure volume, and albumin excretion (Albuwell M kit, Exocell) with modifications of urine dilution to account for increased diuresis in KS-Cul3−/− mice.
Imaging
Fluorescence images were captured with ZEISS AXIO Imager M2 or Keyence BZ-9000 microscopes. Light microscopy images were acquired using an EVOS FL auto-imaging system (Thermo Fischer Scientific). 12 images (200x field or 400x high-power-field, hpf) were randomly taken per kidney cortex and outer medulla. Area fractions and number of cells were calculated using ImageJ and expressed as (%) or number of cells per field.
Statistical analyses
All values are expressed as means ± SEM. For comparison of two groups, two-tailed, unpaired, t-test was used. Protein abundance in IRI-injured kidney was compared to its contralateral control kidney using paired t-test for each time point. Comparison of several groups was performed using ANOVA with Dunnett’s multiple comparisons test. All tests were two-tailed and P < 0.05 was considered significant. All analyses were performed using GraphPad Prism version 6.01.
Supplementary information
Acknowledgements
The funding sources are: DFG German Research Foundation (332853055 to T.S.; TP17, TP25, Q2 to J.F. and M.J.M), Else Kröner-Fresenius Stiftung (2015_A197 to T.S., 2013_A200 to C.K), START by the Medical Faculty of the RWTH Aachen to T.S. (691433), American Heart Association Postdoctoral Fellowship 17POST33670206 to M.Z.F, R01DK051496 to J.D.S, R01DK098141 to J.A.M. The authors would like to acknowledge the technical assistance provided by the Histopathology Shared Resource of Oregon Health & Science University. We thank Lauren Miller and Astrid Fuß for technical support.
Author Contributions
T.S., J.D.S. and J.A.M. designed the study. T.S., C.A.C., M.Z.F, C.K. and J.A.M. performed the experiments and analyzed data. R.K., M.J.M., J.F. and J.D.S. assisted with study design and data interpretation. T.S. and J.A.M. wrote the manuscript, and all authors provided critical comments and had final approval of the submitted and published versions.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary Information Files).
Competing Interests
The authors declare no competing interests.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Turgay Saritas, Email: tsaritas@ukaachen.de.
James A. McCormick, Email: mccormij@ohsu.edu
Supplementary information
Supplementary information accompanies this paper at 10.1038/s41598-019-40795-0.
References
- 1.Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK. Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression. J Am Soc Nephrol. 2015;26:1765–1776. doi: 10.1681/ASN.2015010006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Komander D, Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012;81:203–229. doi: 10.1146/annurev-biochem-060310-170328. [DOI] [PubMed] [Google Scholar]
- 3.Debigare R, Price SR. Proteolysis, the ubiquitin-proteasome system, and renal diseases. Am J Physiol Renal Physiol. 2003;285:F1–8. doi: 10.1152/ajprenal.00244.2002. [DOI] [PubMed] [Google Scholar]
- 4.Uhlen M, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi: 10.1126/science.1260419. [DOI] [PubMed] [Google Scholar]
- 5.Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev. 1999;13:2375–2387. doi: 10.1101/gad.13.18.2375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.McCormick JA, et al. Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3. J Clin Invest. 2014;124:4723-–4736. doi: 10.1172/JCI76126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Genschik P, Sumara I, Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 2013;32:2307–2320. doi: 10.1038/emboj.2013.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Angers S, et al. The KLHL12-Cullin-3 ubiquitin ligase negatively regulates the Wnt-beta-catenin pathway by targeting Dishevelled for degradation. Nat. Cell Biol. 2006;8:348–357. doi: 10.1038/ncb1381. [DOI] [PubMed] [Google Scholar]
- 9.Jiang J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle. 2006;5:2457–2463. doi: 10.4161/cc.5.21.3406. [DOI] [PubMed] [Google Scholar]
- 10.Lee DF, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol. Cell. 2009;36:131–140. doi: 10.1016/j.molcel.2009.07.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ren K, et al. KCTD10 is involved in the cardiovascular system and Notch signaling during early embryonic development. PLoS One. 2014;9:e112275. doi: 10.1371/journal.pone.0112275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell. Biol. 2004;24:8477–8486. doi: 10.1128/MCB.24.19.8477-8486.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sumara I, et al. A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating mitotic progression and completion of cytokinesis in human cells. Dev. Cell. 2007;12:887–900. doi: 10.1016/j.devcel.2007.03.019. [DOI] [PubMed] [Google Scholar]
- 14.Network TCGAR. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med. 2016;374:135–145. doi: 10.1056/NEJMoa1505917. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Boyden LM, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature. 2012;482:98–102. doi: 10.1038/nature10814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Traykova-Brauch M, et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat. Med. 2008;14:979–984. doi: 10.1038/nm.1865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Liu, J. et al. Molecular characterization of the transition from acute to chronic kidney injury following ischemia/reperfusion. JCI Insight2, 10.1172/jci.insight.94716 (2017). [DOI] [PMC free article] [PubMed]
- 18.Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007;47:89–116. doi: 10.1146/annurev.pharmtox.46.120604.141046. [DOI] [PubMed] [Google Scholar]
- 19.Strausser SA, Nakano D, Souma T. Acute kidney injury to chronic kidney disease transition: insufficient cellular stress response. Curr Opin Nephrol Hypertens. 2018;27:314–322. doi: 10.1097/MNH.0000000000000424. [DOI] [PubMed] [Google Scholar]
- 20.Price PM, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int. 2009;76:604–613. doi: 10.1038/ki.2009.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Zhang DD, et al. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J. Biol. Chem. 2005;280:30091–30099. doi: 10.1074/jbc.M501279200. [DOI] [PubMed] [Google Scholar]
- 22.Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. V. & Bonventre, J. V. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat. Med. 16, 535–543, 531p following 143, 10.1038/nm.2144 (2010). [DOI] [PMC free article] [PubMed]
- 23.Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401:297–300. doi: 10.1038/45836. [DOI] [PubMed] [Google Scholar]
- 24.McEvoy JD, Kossatz U, Malek N, Singer JD. Constitutive turnover of cyclin E by Cul3 maintains quiescence. Mol. Cell. Biol. 2007;27:3651–3666. doi: 10.1128/MCB.00720-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kossatz U, et al. The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells. J. Clin. Invest. 2010;120:3820–3833. doi: 10.1172/JCI41959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dulic V, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 1994;76:1013–1023. doi: 10.1016/0092-8674(94)90379-4. [DOI] [PubMed] [Google Scholar]
- 27.Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc. Natl. Acad. Sci. USA. 1998;95:11324–11329. doi: 10.1073/pnas.95.19.11324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kim Y, Starostina NG, Kipreos ET. The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev. 2008;22:2507–2519. doi: 10.1101/gad.1703708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Megyesi J, et al. Increased expression of p21WAF1/CIP1 in kidney proximal tubules mediates fibrosis. Am J Physiol Renal Physiol. 2015;308:F122–130. doi: 10.1152/ajprenal.00489.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cicenas J, et al. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3:135. doi: 10.3978/j.issn.2305-5839.2015.03.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.McClue SJ, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int. J. Cancer. 2002;102:463–468. doi: 10.1002/ijc.10738. [DOI] [PubMed] [Google Scholar]
- 32.Khalil HS, Mitev V, Vlaykova T, Cavicchi L, Zhelev N. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J. Biotechnol. 2015;202:40–49. doi: 10.1016/j.jbiotec.2015.02.032. [DOI] [PubMed] [Google Scholar]
- 33.Tan RJ, et al. Keap1 hypomorphism protects against ischemic and obstructive kidney disease. Sci. Rep. 2016;6:36185. doi: 10.1038/srep36185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.de Zeeuw D, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 2013;369:2492–2503. doi: 10.1056/NEJMoa1306033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Nezu M, et al. Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. Kidney Int. 2017;91:387–401. doi: 10.1016/j.kint.2016.08.023. [DOI] [PubMed] [Google Scholar]
- 36.Sogawa Y, et al. Infiltration of M1, but not M2, macrophages is impaired after unilateral ureter obstruction in Nrf2-deficient mice. Sci. Rep. 2017;7:8801. doi: 10.1038/s41598-017-08054-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Patalano S, et al. CXCL12/CXCR4-Mediated Procollagen Secretion Is Coupled To Cullin-RING Ubiquitin Ligase Activation. Sci. Rep. 2018;8:3499. doi: 10.1038/s41598-018-21506-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol. 2016;311:F145–161. doi: 10.1152/ajprenal.00164.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Becker GJ, Hewitson TD. Animal models of chronic kidney disease: useful but not perfect. Nephrol Dial Transplant. 2013;28:2432–2438. doi: 10.1093/ndt/gft071. [DOI] [PubMed] [Google Scholar]
- 40.Humphreys BD, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J. Clin. Invest. 2013;123:4023–4035. doi: 10.1172/JCI45361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Piret SE, et al. A mouse model for inherited renal fibrosis associated with endoplasmic reticulum stress. Dis. Model. Mech. 2017;10:773–786. doi: 10.1242/dmm.029488. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Hajarnis S, et al. Suppression of microRNA Activity in Kidney Collecting Ducts Induces Partial Loss of Epithelial Phenotype and Renal Fibrosis. J Am Soc Nephrol. 2018;29:518–531. doi: 10.1681/ASN.2017030334. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Kusaba T, Lalli M, Kramann R, Kobayashi A, Humphreys BD. Differentiated kidney epithelial cells repair injured proximal tubule. Proc. Natl. Acad. Sci. USA. 2014;111:1527–1532. doi: 10.1073/pnas.1310653110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Kramann R, et al. Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J. Clin. Invest. 2015;125:2935–2951. doi: 10.1172/JCI74929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Kramann R, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16:51–66. doi: 10.1016/j.stem.2014.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Smeets B, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol. 2009;20:2604–2615. doi: 10.1681/ASN.2009010122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature. 2006;444:949–952. doi: 10.1038/nature05348. [DOI] [PubMed] [Google Scholar]
- 48.Milovanceva-Popovska M, et al. R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury. Kidney Int. 2005;67:1362–1370. doi: 10.1111/j.1523-1755.2005.00213.x. [DOI] [PubMed] [Google Scholar]
- 49.Ferdaus, M. Z. et al. Mutant Cullin 3 causes familial hyperkalemic hypertension via dominant effects. JCI Insight2, 10.1172/jci.insight.96700 (2017). [DOI] [PMC free article] [PubMed]
- 50.McDonough AA, Veiras LC, Minas JN, Ralph DL. Considerations when quantitating protein abundance by immunoblot. Am. J. Physiol. Cell Physiol. 2015;308:C426–433. doi: 10.1152/ajpcell.00400.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Porubsky S, et al. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J. Pathol. 2014;234:120–133. doi: 10.1002/path.4388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Schock-Kusch D, et al. Reliability of transcutaneous measurement of renal function in various strains of conscious mice. PLoS One. 2013;8:e71519. doi: 10.1371/journal.pone.0071519. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data generated or analysed during this study are included in this published article (and its Supplementary Information Files).